RANBAXY Pharmaceuticals has
launched generic pioglitazone
hydrochloride tablets in the US
market, under an agreement with
Takeda Pharmaceuticals.
Pioglitazone hydrochloride tablets
are an oral antidiabetic agent that
acts to decrease insulin resistance.
MEANWHILE the US FDA has also
approved Reckitt Benckiser
Pharmaceuticals’ 4mg and 12mg
doses of Suboxone (buprenorphine
and naloxone) sublingual film,
which is indicated for maintenance
treatment of opioid dependence.The above article was sent to subscribers in Pharmacy Daily's issue from 22 Aug 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Aug 12
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.